Feasibility of rescue stenting technique in patients with acute ischemic stroke due to middle cerebral artery occlusion after failed thrombectomy: A single-center retrospective experience

Jang Hun Kim¹, Jong-Il Choi²*

¹ Department of Neurosurgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea, ² Department of Neurosurgery, Korea University Ansan Hospital, Korea University College of Medicine, Gyeonggi-do, Korea

* thlhd@korea.ac.kr

Abstract

Background

Despite remarkable advancements in intra-arterial mechanical thrombectomy (IAT), recanalization failure rates up to 24% have been reported. Recently, permanent stent placement (rescue stent, RS) during IAT has been suggested as an optional modality for better reperfusion and outcomes in these patients. However, previous studies were limited owing to non-standardized procedure protocols and small sample sizes. Here, we aimed to determine the efficacy and safety of RS in patients with acute ischemic stroke (AIS) with middle cerebral artery (MCA) occlusion.

Methods

Of the 243 patients in our IAT database (2015–2021), 183 were identified as having MCA occlusion alone. Among them, we extracted 53 patients in whom the IAT failed to show thrombolysis in cerebral ischemia (TICI) scores of 2A or worse. Intraoperatively, RS was deployed in 22 patients (RS group), whereas 31 patients (no-stent group) received IAT without stenting. The baseline characteristics and radiologic and clinical outcomes were reviewed. Comparisons between the groups and multivariate logistic analyses for recanalization and good functional outcomes (modified Rankin Scale 0–2) were performed.

Results

No baseline differences were noted (RS vs. no-stent); however, the recanalization outcomes (59.1% vs. 25.8%, p = 0.15) and proportion of good modified Rankin Scale scores (45.5% vs. 19.4%, p = 0.041) were better in the RS group. The parameters of symptomatic ICH (9.7% vs. 9.4%) and mortality (6.5% vs. 5.7%) showed no significant difference. In the
multivariate analyses, ‘hypertension’ and ‘RS deployment’ were identified as significantly associated factors with recanalization and good prognosis.

**Conclusion**

In select patients with MCA occlusion AIS after failed IAT, the RS technique can be an optional rescue treatment modality for acquiring better functional outcomes and delayed recanalization.

**Introduction**

Intra-arterial mechanical thrombectomy (IAT) is now a standard first-choice therapy for effective recanalization in patients with acute ischemic stroke (AIS) with large vessel occlusion (LVO) within the recently extended time window of 24 h after symptom onset [1, 2]. Compared to medical treatment, IAT is superior with respect to reperfusion of salvageable brain tissue [3–6]. However, despite remarkable advancements in IAT techniques, failure rates of up to 24% have been reported [1, 2]. Recently, permanent placement of a self-expanding stent, the so-called “rescue stent (RS)” technique, has been suggested as an optional modality for failed reperfusion patients and is associated with good outcomes without increasing morbidity or mortality [7–11]. However, previous studies were limited owing to the heterogeneity of the location of the occlusion site, peri-procedural protocols, and small numbers.

We hypothesized that the standardized RS technique would be effective, especially in patients with middle cerebral artery (MCA) occlusion who have undergone failed thrombectomy. It is well understood that underlying ‘atherosclerotic or calcified’ intracranial arterial stenosis (ICAS), which is frequently observed in the MCA, can lead to a higher risk of thrombectomy failure [12]. In this situation, permanent deployment of the stent can be beneficial for widening the arterial diameter; thus, the plasminogen effect can be initiated at thrombosed sites [13]. Consequently, it can salvage a larger volume of the ischemic penumbra in patients prone to ongoing infarction. Herein, we attempted to identify the efficacy of RS by comparing failed thrombectomy patients with deployment of RS to those without.

**Methods**

**Patients**

Among 243 patients who were diagnosed with AIS due to LVO and who were eligible for emergent IAT from March 2015 to February 2021, we retrospectively extracted 53 patients according to the enrolled criteria: (1) those who were identified as having LVO of the ‘MCA alone’ (2) with confirmed ‘failed’ IAT procedures. ‘Failed thrombectomy’ was defined when thrombolysis in cerebral ischemia (TICI) scores of ‘2A or worse’ were noted at the final angiography after sufficient stentretrieving with or without contact aspiration [14]. Patients were excluded if they had other site occlusions (tandem occlusion) or had successful TICI reactivation scores of 2B–3. Tandem occlusion is defined as the lesion involved not only the extracranial (cervical) part of the internal carotid artery (ICA) but also concomitant thromboembolism of its intracranial distal segment or MCA [15]. A flowchart of patient enrolment is shown in Fig 1.

From the case report form (CRF) of our database, we collected data including general information (age, sex, and past medical history), National Institutes of Health Stroke Scale (NIHSS) score at admission, procedural data (use of intravenous tissue plasminogen activator [tPA],
onset-to-puncture time, procedure time, and number of retrieval attempts), and clinical course data. Outcomes were evaluated using mortality rates and modified Rankin Scale (mRS) scores 3 months after the intervention.
Ethics statement

The current study was approved by the Institutional Review Board of the Human Research Center of Korea University Ansan Hospital and the given number of the study is 2022AS0146.

Informed consent

In every case, informed consent was obtained just before surgery. Patients or legal guardians were informed that the IATs were tailored according to the patient-specific characteristics determined from the clinical and radiological findings and that permanent stents can be deployed with limited evidence. It was obtained by the written forms and the possible side effects and benefits were fully explained.

Procedures

The IAT procedure was performed under local anesthesia with or without mild conscious sedation, according to the patient’s status. The procedure was performed by two independent interventionists. Usually, the target vessel IAT can be directly initiated without performing routine four-vessel angiography, as preoperative computed tomography angiography (CTA) was preoperatively evaluated. A balloon-guiding catheter (8Fr Cello, Covidien/ev3, Irvine, CA, USA) was placed in the relevant cervical ICA, and the intermediate catheter (6Fr Sofia, Microvention, Aliso Viejo, CA) was navigated to the distal ICA or proximal middle cerebral artery (MCA) according to the surgeon’s decision. Contact aspiration thrombectomy was performed after balloon inflation. The procedure was terminated if successful (TICI IIB–III) aspiration was performed. If contact aspiration was unsuccessful, stentriever thrombectomy was followed with Solitaire FR (Covidien/ev3, Irvine, CA) or Trevo Proview stents (Stryker, Fremont, CA). In this situation, continuous intravenous tirofiban (Aggrastat, Medicure Pharma, Princeton, NJ) infusion was administered without exception (loading: 0.4 mcg/kg/min for 30 minutes, maintenance: 0.1 mcg/kg/min for 4–6 hours). At least two to five retrievals were conducted, and angiography was performed to evaluate the TICI score. If thrombectomy was successful (TICI IIB to III), repetitive confirmative angiography was performed 15 min later. When patients presented refractory occlusion after several retrievals (TICI 0 to IIA), the physician decided whether to perform permanent stenting (RS) or stop the operation. Two different protocols were used according to the surgeon’s preference: (1) RS and (2) no-stent. In the RS group, the self-expandable Solitaire FR stent was permanently detached in the usual manner, fully covering the expected stenotic or occluded sites of the MCAs (Fig 2). Owing to possible insurance issues, the Wingspan stent (Stryker, Fremont, CA, USA) was not used.

Radiologic evaluations

Before the procedure, head and neck computed tomography (CT), including CTA and perfusion CT (CTP), and magnetic resonance diffusion-weighted imaging (DWI), were performed to identify the infarction core, ischemic penumbra, perfusion-diffusion mismatch (PDM), and origin of the stroke. Perfusion-delayed areas were measured using mean transient time (MTT) CTP sequences, and diffusion restrictions were defined as high signal intensity lesions with b-values of 1000 s/mm$^2$ in echo-planar DWI sequences (Fig 3A) using the Alberta Stroke Program Early CT Score (ASPECTS) system [16]. Using the ASPECTS system, [16] PDM was defined as differences of more than 2 points between CTP and DWI [17].

After the IAT procedure, a subsequent CT scan (or DWI) was performed within 48 hours and 7 to 10 days after the onset of stroke or whenever neurological deterioration occurred. A hemorrhage was considered as symptomatic intracranial hemorrhage (sICH) if it was not seen...
**Fig 2. Intraoperative angiograms during RS deployment.** The angiogram shows occlusion of the left M2 superior branch (A). The micro-angiogram visualizes the peripheral arterial flows after passing the occlusion site (B). Despite several attempts at stent deploying and retrieving (C), failed thrombectomy of TICI 0 is observed (D). Finally, the RS is permanently deployed (E), and recanalization of the superior M2 is shown after 15 minutes in an angiogram (F). RS, rescue stent; TICI, thrombolysis in cerebral ischemia.

https://doi.org/10.1371/journal.pone.0274842.g002

**Fig 3. Radiologic images of a patient before and after RS deployment.** Before IAT, diffusion-perfusion mismatch was identified by comparing the DWI to CTP images (A). Three months after the procedure, recanalization of M2 was noted on CTA. RS, rescue stent; IAT, intra-arterial thrombectomy; DWI, diffusion-weighted image; CTP, perfusion computed tomography; CTA, computed tomographic angiography.

https://doi.org/10.1371/journal.pone.0274842.g003
on a previous CT scan and there had subsequently been either a suspicion of hemorrhage or any decline in neurologic status (≥ 4 point increase in the total NIHSS score or an increase ≥ 2 points in one NIHSS category) [18]. Three months after the procedure, angiographic studies (CTA, MRA, or DSA) were performed to evaluate the recanalization. Recanalization was defined as the absence of vessel occlusion and prominent visualization of the distal vessels in the following images (Fig 3B).

**Statistical analysis**

Continuous values were presented as means and standard deviations, and categorical variable data were presented as numbers and percentages. A comparison analysis was performed between the two groups (RS vs. no-stent groups). In addition, univariate and multivariate logistic regression analyses were conducted to identify the factors associated with good functional outcomes and recanalization. Statistical significance was set at \( p < 0.05 \). Statistical analyses were performed using standard software (version 23.0, SPSS, IBM, Chicago, IL, USA).

**Results**

Among 183 reviewed patients who were diagnosed with LVO-AIS at the MCA, 130 (71%) achieved successful recanalization of TICI 2B to 3. However, 53 enrolled patients (29%) remained non-recanalized after contact aspiration and stentriever thrombectomy (TICI 0 to 2A). The general demographics of the enrolled patients and the results of the comparative analysis between the groups are presented in Table 1. The mean age of the patients was 67 years, and two-thirds of the patients had pathologies of the M1 segments. The initial NIHSS and ASPECTS scores were 14.89 and 7.75, respectively. In terms of the outcomes of the enrolled patients, only 16 patients (30.2%) achieved good mRS scores (0–2) at 3 months, and 3 patients (5.7%) died.

In the comparison analysis, baseline characteristics related to patient information, clinical and radiologic features, and procedure-related data showed no significant differences between the groups. However, in terms of outcomes, patients in the RS group showed higher recanalization (59.1% vs. 25.8%, \( p = 0.15 \)) and good mRS scores at 3 months (45.5% vs. 19.4%, \( p = 0.041 \)) compared to those in the no-stent group. The parameters of symptomatic sICH (9.7% vs. 9.4%) and mortality (6.5% vs. 5.7%) showed no significant differences.

Table 2 presents the results of the univariate and multivariate logistic regression analyses performed to identify the factors associated with a good mRS score at 3 months. In the present study, hypertension (\( p = 0.007 \)) and RS deployment (\( p = 0.042 \)) were identified as independent prognostic factors for better functional outcomes.

Table 3 presents the results of the logistic regression analyses for recanalization. Similar to previous results, parameters of hypertension (\( p = 0.005 \)) and RS deployment (\( p = 0.016 \)) were identified as significant factors associated with recanalization.

**Discussion**

The current study demonstrated the efficacy of deploying RS in select patients with LVO-AIS after failed IAT. Patients in the RS group showed significantly better outcomes, good mRS scores at 3 months, and recanalization during follow-up without increased risks of symptomatic ICH or mortality. In addition, hypertension and RS deployment were identified as independent factors associated with recanalization and good mRS scores. This suggests that the RS technique can be a rescue treatment modality for thrombectomy-failed MCA-occlusion in AIS.
Several previous studies have evaluated the efficacy and safety of permanent stenting in LVO [19–21]. However, the efficacy of RS in selective AIS patients with failed IAT was recently investigated [9, 10, 22], and most studies reported favorable outcomes in patients with RS. Despite the proven efficacy of recent studies, the RS technique is not the optimal treatment method because of the lack of randomized trials and prospective study designs. The current investigation is a single-center, retrospectively analyzed study that focused on intracranial RS deployment in the MCA. To acquire more evidence of the efficacy of the RS technique, we strictly followed the procedure protocols and standardized every periprocedural setting, except RS deployment, according to the surgeons’ preferences.

Based on the results of recent clinical trials, IAT is now a standard first-line treatment for effective recanalization in select patients with LVO-AIS within the recently extended time window of 24 h after symptom onset [1, 2]. It is clear that IAT is superior with respect to reperfusion of salvageable brain tissue compared to medical therapy alone [3–6]. However, despite remarkable advancements in IAT techniques, a failure rate of up to 24% has been reported in these two trials, and the medical arm of patients (failed IAT patients) showed dismal outcomes [1, 2]. Irrespective of the cause of refractoriness in LVO-AIS, a rescue modality is needed for such refractory cases. In this situation, RS can be ‘easily’ and ‘intraoperatively’ attempted without excessive time consumption or risks [8, 10].

### Table 1. Results of comparative analysis between the rescue stent and no-stent groups.

| Parameters                      | Enrolled patients (N = 53) | No-stent group (N = 31) | Rescue stent group (N = 22) | Mean differences or odds ratio | 95% Confidence interval | p-value |
|---------------------------------|-----------------------------|-------------------------|----------------------------|--------------------------------|-------------------------|---------|
| **Patients**                    |                             |                         |                            |                                |                         |         |
| Age                             | 67.62 ±5.350                | 68.32 ±5.160            | 66.64 ±5.577               | 1.686                          | -1.300 – 4.672          | 0.262   |
| Female sex                      | 23 (43.4%)                  | 13 (41.9%)              | 10 (45.5%)                 | 1.154                          | 0.384 – 3.471           | 0.799   |
| HTN                             | 30 (56.6%)                  | 17 (54.8%)              | 13 (59.1%)                 | 1.190                          | 0.394 – 3.594           | 0.758   |
| DM                              | 18 (34.0%)                  | 11 (35.5%)              | 7 (31.8%)                  | 0.848                          | 0.266 – 2.707           | 0.781   |
| DL                              | 18 (34.0%)                  | 9 (29.0%)               | 9 (40.9%)                  | 1.692                          | 0.536 – 5.348           | 0.368   |
| Smoking history                 | 14 (26.4%)                  | 8 (25.8%)               | 6 (27.3%)                  | 1.078                          | 0.313 – 3.710           | 0.905   |
| Previous stroke                 | 6 (11.3%)                   | 4 (12.9%)               | 2 (9.1%)                   | 0.675                          | 0.112 – 4.056           | 0.666   |
| A.fib                           | 15 (28.3%)                  | 9 (29.0%)               | 6 (27.3%)                  | 0.917                          | 0.271 – 3.096           | 0.889   |
| **Clinical and radiologic features** |                     |                         |                            |                                |                         |         |
| Location                        |                             |                         |                            |                                |                         |         |
| M1                              | 35 (66.0%)                  | 20 (64.5%)              | 15 (68.2%)                 | 0.848                          | 0.266 – 2.707           | 0.781   |
| (superior)                      | 13 (24.6%)                  | 8 (25.8%)               | 5 (22.7%)                  | 0.848                          | 0.266 – 2.707           | 0.781   |
| (inferior)                      | 5 (9.4%)                    | 3 (97%)                 | 2 (9.1%)                   | 0.917                          | 0.271 – 3.096           | 0.889   |
| NIHSS                           | 14.89 ±2.407                | 14.77 ±2.539            | 15.05 ±2.257               | -0.271                         | -1.629 – 1.087          | 0.690   |
| ASPECTS                         | 7.75 ±1.108                 | 7.71 ±1.243             | 7.82 ±0.907                | -0.109                         | -0.734 – 0.517          | 0.729   |
| **Procedures**                  |                             |                         |                            |                                |                         |         |
| tPA                             | 24 (45.3%)                  | 13 (41.9%)              | 11 (50.0%)                 | 1.385                          | 0.461 – 4.155           | 0.561   |
| Onset-to-puncture time          | 246.89 ±45.428              | 241.29 ±41.332          | 254.77 ±50.344             | -13.482                        | -38.873 – 11.908        | 0.291   |
| Procedure time                  | 123.21 ±12.329              | 123.23 ±11.295          | 123.18 ±13.934             | 0.044                          | -6.924 – 7.011          | 0.990   |
| Number of retrieval attempts    | 2.91 ±0.450                 | 2.94 ±0.442             | 2.86 ±0.468                | 0.072                          | -0.182 – 0.325          | 0.572   |
| **Outcomes**                    |                             |                         |                            |                                |                         |         |
| Recanalization                  | 21 (39.6%)                  | 8 (25.8%)               | 13 (59.1%)                 | 4.153                          | 1.289 – 13.384          | 0.015   |
| Symptomatic ICH                 | 5 (9.4%)                    | 3 (9.7%)                | 2 (9.1%)                   | 0.933                          | 0.143 – 6.110           | 0.943   |
| Good mRS (0–2) at 3 months      | 16 (30.2%)                  | 6 (19.4%)               | 10 (45.5%)                 | 3.472                          | 1.021 – 11.808          | 0.041   |
| Mortality                       | 3 (5.7%)                    | 2 (6.5%)                | 1 (4.5%)                   | 0.690                          | 0.059 – 8.125           | 0.767   |

https://doi.org/10.1371/journal.pone.0274842.t001
In our study, RS patients presented more favorable functional outcomes (45.5% good mRS scores) than those without stents (19.4%). This may be related to the higher incidence of delayed recanalization of the occluded MCAs (59.1% vs 25.8%). Owing to the self-expanding characteristics of the stent itself, narrow arteries can be widened irrespective of the underlying pathologies [13]. This can lead to fresh blood delivered to the pathologic site with antegrade and retrograde flows. Physiologically, a thrombus or embolic material can be degraded only when plasmin is activated [23]. Delivering blood (or plasminogen) to the pathologic site is essential for recanalization, even if it is a small amount.

We can assume that MCA occlusion is possibly related to embolism or thrombus formation, with or without underlying stenosis. It is often not possible to distinguish between a hard thrombus and intracranial stenosis during the procedure, although there are studies that consider truncal occlusion to have an underlying intracranial stenosis when all branches and bifurcations are clearly visible beyond the occluded segment [22, 24]. However, in the selected patients (failed IAT), we can speculate that underlying intracranial stenosis would exist much more frequently, as it is difficult to pass the occlusion site owing to the underlying calcification or atherosclerotic luminal irregularity on the artery [25]. In this situation, additional permanent stenting would be performed on the underlying stenotic site, which might induce delayed recanalization of the occluded vessel by enlarging the arterial lumen and guiding the inflow of blood.

Stent deployment is sometimes accompanied by the possible side effects of intimal injury, procedure-related thrombosis, and delayed in-stent restenosis. In our protocol, the procedure was strictly performed by covering with intravenous tirofiban. Tirofiban is classified as a platelet aggregation inhibitor that interferes with protein-protein interactions between fibrinogen and platelet integrin receptor GP IIb/IIIa. Recent studies have shown very promising results.

### Table 2. Results of univariate and multivariate analyses for identifying factors associated with good functional outcomes (3-month mRS 0–2).

| Parameters                  | Poor mRS (n = 37) | Good mRS (n = 16) | Univariate analysis | Multivariate analysis |
|-----------------------------|-------------------|-------------------|---------------------|-----------------------|
| Patients                    |                   |                   | Hazard Ratio 95% CI | p-value | Hazard Ratio 95% CI | p-value |
| Age                         | 68.22 ± 5.239     | 66.25 ± 5.520     | 0.929 0.824 1.046   | 0.222 | 0.480 0.139 1.655   | 0.245   |
| Female sex                  | 18 (48.6%)        | 5 (31.3%)         | 0.839 0.239 2.941   | 0.784 | 2.700 0.798 9.139   | 0.110   |
| HTN                         | 16 (43.2%)        | 14 (87.5%)        | 9.187 1.822 46.336  | 0.007* | 10.531 1.932 57.409 | 0.007*  |
| DM                          | 13 (35.1%)        | 5 (31.3%)         | 0.839 0.239 2.941   | 0.784 | 3.333 0.922 12.055  | 0.066*  |
| DL                          | 10 (27.0%)        | 8 (50.0%)         | 2.700 0.798 9.139   | 0.110 | 1.179 0.193 7.193   | 0.859   |
| Smoking history             | 7 (18.9%)         | 7 (43.8%)         | 3.333 0.922 12.055  | 0.066* | 2.894 .641 13.059  | 0.167   |
| Previous stroke             | 4 (10.8%)         | 2 (12.5%)         | 1.179 0.193 7.193   | 0.859 | 1.867 0.529 6.583   | 0.332   |
| A.fib                       | 9 (24.3%)         | 6 (37.5%)         | 1.867 0.529 6.583   | 0.332 |
| Clinical and radiologic features |             |                   |                     |         |
| Location                    |                   |                   |                     |         |
| M1                          | 24 (64.9%)        | 11 (68.8%)        | 0.839 0.239 2.941   | 0.784 |                     |         |
| M2                          | 13 (35.1%)        | 5 (31.3%)         | 0.839 0.239 2.941   | 0.784 |                     |         |
| NIHSS                       | 15.03 ± 2.651     | 14.56 ± 1.750     | 0.920 0.716 1.183   | 0.517 | 0.923 0.539 1.579   | 0.770   |
| ASPECTS                     | 7.78 ± 1.058      | 7.69 ± 1.250      | 0.923 0.539 1.579   | 0.770 |                     |         |
| Procedures                  |                   |                   |                     |         |
| tPA                         | 14 (37.8%)        | 10 (62.5%)        | 2.738 0.816 9.189   | 0.103 |                     |         |
| Onset-to-puncture time      | 247.16 ± 37.016   | 246.25 ± 62.169   | 1.000 0.987 1.013   | 0.946 |                     |         |
| Procedure time              | 123.11 ± 12.982   | 123.44 ± 11.063   | 1.002 0.955 1.051   | 0.928 |                     |         |
| Number of retrieval attempts| 2.89 ± 0.458      | 2.94 ± 0.443      | 1.262 0.332 4.786   | 0.733 |                     |         |
| Rescue stent                | 12 (32.4%)        | 10 (62.5%)        | 3.472 1.021 11.808  | 0.046* | 4.182 1.050 16.656  | 0.042*  |

https://doi.org/10.1371/journal.pone.0274842.t002
regarding the safety of intravenous tirofiban during stent deployment, including lowering of the incidence of procedure-related thrombosis without any increase in symptomatic ICHs [26, 27]. In addition, the RS technique requires only one additional catheter passing through the pathologic artery and stent deployment while pulling backward, and the procedural yield is suspected to be much higher considering the small side effects. We can conclude that procedure-related complications can be effectively prevented by administering intravenous tirofiban during the procedure.

Interestingly, a previous history of hypertension was additionally identified as an indicator of recanalization and good mRS scores in multivariate analyses. In acute stroke management, blood pressure should be lowered to maintain blood flow to the ischemic penumbra [28]. After deploying RSs in patients, avoiding low blood pressure is important for reducing in-stent thrombosis and inducing delayed recanalization. However, in the literature, the association between hypertension and functional outcomes or recanalization is controversial [29, 30]. Future investigations with a larger cohort are warranted to identify the mechanism of hypertension in patients with LVA-AIS with or without RS.

The current study has several limitations. First, our results cannot be generalized because of the small number of retrospectively enrolled patients and the lack of a multi-centered design involving the participation of multiple physicians. A prospectively designed randomized trial with a larger cohort is necessary to develop evidence for RS as an optimal treatment. Second, only 3-month mRS scores were reviewed, and the long-term efficacy of RS was not evaluated. Since intracranial stent insertion can induce delayed in-stent restenosis, patients should be followed up. Third, only the Solitaire stent was used because of insurance issues. If more evidence is accumulated, an appropriate stent can be chosen.

Table 3. Results of univariate and multivariate analyses for identifying factors associated with recanalization.

| Parameters       | No recanalization (n = 32) | Recanalization (n = 21) | Univariate analysis | Multivariate analysis |
|------------------|---------------------------|------------------------|---------------------|----------------------|
|                  | Hazard Ratio | 95% CI | P-value | Hazard Ratio | 95% CI | P-value |
| Patients         | Age          | ±4.900  | ±6.005  | 0.952     | 0.855  | 1.060  | 0.369 |
|                  | Female sex   | (43.8%) | (42.9%) | 0.964     | 0.317  | 2.929  | 0.949 |
|                  | HTN          | (40.6%) | (81.0%) | 6.212     | 1.697  | 22.739 | 0.006* |
|                  | DM           | (34.4%) | (33.3%) | 0.955     | 0.298  | 3.058  | 0.938 |
|                  | DL           | (28.1%) | (42.9%) | 1.917     | 0.602  | 6.101  | 0.271 |
|                  | Smoking history | (18.8%) | (38.1%) | 2.667     | 0.764  | 9.312  | 0.124 |
|                  | Previous stroke | (9.4%) | (14.3%) | 1.611     | 0.293  | 8.863  | 0.584 |
|                  | A.fib        | (25.0%) | (33.3%) | 1.500     | 0.447  | 5.029  | 0.511 |
| Clinical and radiologic features | Location | M1 | (59.4%) | 16 (76.2%) | 0.457 | 0.134 | 1.558 | 0.211 |
|                  | M2           | (40.6%) | 5 (23.8%) | 0.991     | 0.787  | 1.249  | 0.942 |
|                  | NIHSS        | ±2.347  | ±2.555  | 0.991     | 0.787  | 1.249  | 0.942 |
|                  | ASPECTS      | ±1.008  | ±1.248  | 0.772     | 0.459  | 1.298  | 0.329 |
| Procedures       | tPA          | 15 (46.9%) | 9 (42.9%) | 0.850     | 0.281  | 2.576  | 0.774 |
|                  | Onset-to-puncture time | 251.25 | ±42.635 | 240.24  | ±49.711 | 0.994 | 0.982 | 1.007 | 0.387 |
|                  | Procedure time | 122.97 | ±12.106 | 123.57  | ±12.956 | 1.004 | 0.960 | 1.050 | 0.861 |
|                  | Number of retrieval attempts | 2.84  | ±0.448  | 3.00  | ±0.447  | 2.317 | 0.597 | 8.986 | 0.224 |
|                  | Rescue stent | 9 (28.1%) | 13 (61.9%) | 4.153     | 1.289  | 13.384 | 0.017* |

https://doi.org/10.1371/journal.pone.0274842.t003
Conclusion
In select patients with MCA-occlusion AIS after failed IAT, the RS technique can be an optional rescue treatment modality for acquiring better functional outcomes and delayed recanalization.

Supporting information
S1 Data.
(XLSX)

Author Contributions
Conceptualization: Jang Hun Kim.
Data curation: Jong-Il Choi.
Formal analysis: Jang Hun Kim.
Funding acquisition: Jang Hun Kim, Jong-Il Choi.
Investigation: Jang Hun Kim.
Methodology: Jang Hun Kim.
Project administration: Jang Hun Kim.
Resources: Jang Hun Kim.
Software: Jang Hun Kim.
Supervision: Jong-Il Choi.
Visualization: Jang Hun Kim.
Writing – original draft: Jang Hun Kim.
Writing – review & editing: Jong-Il Choi.

References
1. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018; 378(1):11–21. Epub 2017/11.4. https://doi.org/10.1056/NEJMoa1706442 [pii]. PMID: 29129157.
2. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018; 378(8):708–18. Epub 2018/01/25. https://doi.org/10.1056/NEJMoa1713973 PMID: 29364767.
3. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012; 380(9849):1231–40. Epub 2012/08/31. https://doi.org/10.1016/S0140-6736(12)61299-9 S0140-6736(12)61299-9 [pii]. PMID: 22932714; PubMed Central PMCID: PMC4176618.
4. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015; 372(11):1019–30. Epub 2015/02/12. https://doi.org/10.1056/NEJMoa1414905 PMID: 25671798.
5. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015; 372(24):2285–95. Epub 2015/04/18. https://doi.org/10.1056/NEJMoa1415061 PMID: 25882376.
6. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015; 372(1):11–20. Epub 2014/12/18. https://doi.org/10.1056/NEJMoa1411587 PMID: 25517348.
7. Cornelissen SA, Andersson T, Holmberg A, Brouwer PA, Soderman M, Bhogal P, et al. Intracranial Stenting after Failure of Thrombectomy with the emboTrap(R) Device. Clin Neuroradiol. 2019; 29(4):677–83. Epub 2018/05/31. https://doi.org/10.1007/s00062-018-0697-x PMID: 29845367; PubMed Central PMCID: PMC6884426.

8. Peng F, Wan J, Liu W, Huang W, Wang L, Qiu T, et al. Efficacy and safety of rescue stenting following failed mechanical thrombectomy for anterior circulation large vessel occlusion: propensity score analysis. J Neurointerv Surg. 2020; 12(3):271–3. Epub 2019/09/19. https://doi.org/10.1111/neurintsur.2019-01515 PMID: 31530654.

9. Baek JH, Kim BM, Kim DJ, Heo JH, Nam HS, Yoo J. Stenting as a Rescue Treatment After Failure of Mechanical Thrombectomy for Anterior Circulation Large Artery Occlusion. Stroke. 2016; 47(9):2360–3. Epub 2016/07/23. https://doi.org/10.1161/STROKEAHA.116.014073 PMID: 27444259.

10. Chang Y, Kim BM, Bang OY, Baek JH, Heo JH, Nam HS, et al. Rescue Stenting for Failed Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter Experience. Stroke. 2018; 49(4):958–64. Epub 2018/03/28. https://doi.org/10.1161/STROKEAHA.117.020072 PMID: 29581342.

11. Baracchini C, Farina F, Soso M, Viero F, Favaretto S, Palmieri A, et al. Stentriever Thrombectomy Failure: A Challenge in Stroke Management. World Neurosurg. 2017; 103:57–64. Epub 2017/03/30. https://doi.org/10.1016/j.wneu.2017.03.070 PMID: 28347898.

12. Kang DH, Yoon W, Baek BH, Kim SK, Lee YY, Kim JT, et al. Front-line thrombectomy for acute large-vessel occlusion with underlying severe intracranial stenosis: stent retriever versus contact aspiration. J Neurosurg. 2019; 132(4):1202–8. Epub 2019/03/30. https://doi.org/10.3171/2019.1.JNS182905 PMID: 30925471.

13. Mitelf F, Faulder KC, Goh AC, Steinfort BS, Sue C, Harrington TJ. Mechanical thrombectomy with a self-expanding retrievable intracranial stent (Solitaire AB): experience in 26 patients with acute cerebral artery occlusion. AJNR Am J Neuroradiol. 2011; 32(6):1078–81. Epub 2011/04/16. https://doi.org/10.3174/ajnr.A2447 PMID: 21493763; PubMed Central PMCID: PMC8013140.

14. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003; 34(8):e109–37. Epub 2003/07/19. https://doi.org/10.1161/01.STR.0000082721.62796.09 PMID: 12869717.

15. Wilson MP, Murad MH, Kings T, Pereira VM, O’Kelly C, Rempel J, et al. Management of tandem occlusions in acute ischemic stroke—intracranial versus extracranial first and extracranial stenting versus angioplasty alone: a systematic review and meta-analysis. J Neurointerv Surg. 2018; 10(8):721–8. Epub 2018/03/11. https://doi.org/10.1136/neurintsurg-2017-013707 PMID: 29523749.

16. Putz V, Dzialowski I, Hill MD, Demchuk AM. The Alberta Stroke Program Early CT Score in clinical practice: what have we learned? Int J Stroke. 2009; 4(5):354–64. Epub 2009/09/22. https://doi.org/10.1111/j.1747-4949.2009.00337.x [pii]. PMID: 19765124.

17. Lassalle L, Turg G, Tissierand M, Charron S, Roca P, Lion S, et al. ASPECTS (Alberta Stroke Program Early CT Score) Assessment of the Perfusion-Diffusion Mismatch. Stroke. 2016; 47(10):2553–8. Epub 2016/09/15. https://doi.org/10.1161/STROKEAHA.116.013676 [pii]. PMID: 27625381.

18. National Institute of Neurological D, Stroke n PASSG. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581–7. Epub 1995/12/14. https://doi.org/10.1056/NEJM199512243332401 PMID: 7477192.

19. Brekenfeld C, Schroth G, Mattle HP, Do DD, Remonda L, Mordasin P, et al. Stent placement in acute cerebral artery occlusion: use of a self-expandable intracranial stent for acute stroke treatment. Stroke. 2009; 40(3):847–52. Epub 2009/02/03. https://doi.org/10.1161/STROKEAHA.108.533810 PMID: 19182080.

20. Mocco J, Hanel RA, Sharma J, Hauck EF, Snyder KV, Natarajan SK, et al. Use of a vascular reconstruction device to salvage acute ischemic occlusions refractory to traditional endovascular recanalization methods. J Neurol Surg. 2010; 111(3):557–62. Epub 2009/09/22. https://doi.org/10.3171/2009.8.JNS09231 PMID: 19765124.

21. Ziaidyat AO, Wolfe T, Hussian SI, Lynch JR, Gupta R, Delap J, et al. Interventional acute ischemic stroke therapy with intracranial self-expanding stent. Stroke. 2008; 39(8):2392–5. Epub 2008/06/17. https://doi.org/10.1161/STROKEAHA.107.510966 PMID: 18556584.

22. Perez-Garcia C, Gomez-Escalonilla C, Rosati S, Lopez-Ibor L, Egido JA, Simal P, et al. Use of intracranial stent as rescue therapy after mechanical thrombectomy failure-9-year experience in a comprehensive stroke centre. Neuroendocrinology. 2020; 62(11):1475–83. Epub 2020/07/02. https://doi.org/10.1007/s00253-020-02487-9 PMID: 32607747.

23. Humpich M, Singer OC, du Mesnil de Rochemont R, Foerch C, Lanermann H, Neumann-Haefelin T. Effect of early and delayed recanalization on infarct pattern in proximal middle cerebral artery occlusion. Cerebrovasc Dis. 2006; 22(1):51–6. Epub 2006/03/29. https://doi.org/10.1159/000092338 PMID: 16567938.
24. Baek JH, Kim BM, Heo JH, Kim DJ, Nam HS, Kim YD. Outcomes of Endovascular Treatment for Acute Intracranial Atherosclerosis-Related Large Vessel Occlusion. Stroke. 2018; 49(11):2699–705. Epub 2018/10/26. https://doi.org/10.1161/STROKEAHA.118.022327 PMID: 30355204.

25. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013; 12(11):1106–14. Epub 2013/10/19. https://doi.org/10.1016/S1474-4422(13)70195-9 PMID: 24135208; PubMed Central PMCID: PMC4005874.

26. Sun L, Zhang J, Song Y, Zhao W, Zheng M, Zhang J, et al. Safety and efficacy of prophylactic tirofiban infusion for acute intracranial intraprocedural stent thrombosis. Sci Rep. 2021; 11(1):21326. Epub 2021/10/31. https://doi.org/10.1038/s41598-021-00872-9 PMID: 34716365; PubMed Central PMCID: PMC8556246.

27. Tang L, Tang X, Yang Q. The Application of Tirofiban in the Endovascular Treatment of Acute Ischemic Stroke: A Meta-Analysis. Cerebrovasc Dis. 2021; 50(2):121–31. Epub 2021/01/06. https://doi.org/10.1159/000512601 PMID: 33401276.

28. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockcroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52(7):e364–e467. Epub 2021/05/25. https://doi.org/10.1161/STR.0000000000000375 PMID: 34024117.

29. Sung SM, Lee TH, Cho HJ, Cho GY, Jung DS, Lee JI, et al. Clinical predictors for favorable outcomes from endovascular recanalization in wake-up stroke. J Clin Neurosci. 2017; 41:66–70. Epub 2017/03/07. https://doi.org/10.1016/j.jocn.2017.02.021 PMID: 28262403.

30. Deng G, Xiao J, Yu H, Chen M, Shang K, Qin C, et al. Predictors of futile recanalization after endovascular treatment in acute ischemic stroke: a meta-analysis. J Neurointerv Surg. 2021. Epub 2021/09/22. https://doi.org/10.1136/neurintsurg-2021-017963 PMID: 34544824.